Leukemia Articles | Page 2

Ibrutinib, Venetoclax, and Obinutuzumab Triplet Safe, Effective as Initial CLL Therapy
Kerry A. Rogers, MD, discusses the promise of the obinutuzumab, ibrutinib, and venetoclax triplet as a first-line treatment for patients with chronic lymphocytic leukemia.
IKZF1 Deletions Predict Poor Prognosis in Pediatric ALL
IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion (IKZF1plus) were associated with a dramatically reduced prognosis in pediatric patients with B-cell precursor ALL. 
 
Expert Highlights Game-Changing Therapies for Acute Leukemia
William Donnellan, MD, discusses recent FDA approvals for the treatment of patients with AML and ALL, and highlighted emerging agents in the pipeline.
Davids Discusses Frontline CLL Combo of Ibrutinib Plus Chemoimmunotherapy
Matthew S. Davids, MD, discusses the key results of ibrutinib (Imbruvica) with standard frontline chemoimmunotherapy in CLL. 
Gemtuzumab Ozogamicin Approaches EU Approval for CD33+ AML
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of gemtuzumab ozogamicin for use in combination with daunorubicin and cytarabine as a frontline treatment for patients aged 15 years and older with previously untreated, de novo CD33-positive acute myeloid leukemia, except acute promyelocytic leukemia.
Bosutinib Nears EU Approval for Frontline Ph+ CML
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of bosutinib (Bosulif) as a first-line treatment for patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Flinn Highlights Emerging Combinations in CLL
Ian W. Flinn, MD, discusses ongoing advances with emerging combination regimens in chronic lymphocytic leukemia.
Umbralisib Shows Early Promise in CLL and Lymphoma
The PI3K-delta inhibitor umbralisib (TGR-1202) induced an objective response rate of 37% in patients with relapsed/refractory lymphoma or chronic lymphocytic leukemia.
Combinations Continue to Push CLL Field Forward
Jacqueline C. Barrientos, MD, discusses recent combination trials in CLL, and emerging agents in the pipeline.
FDA Panel to Review Blinatumomab Application for MRD-positive ALL
The FDA's Oncologic Drugs Advisory Committee is slated to review a supplemental biologics license application for the use of blinatumomab for the treatment of patients with minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia.
Publication Bottom Border
Border Publication
x